OBJECTIVES: Extracorporeal life support (ECLS) devices provide temporary mechanical circulatory assistance and are usually implanted under emergency conditions in critical patients. If weaning off ECLS is not possible, heart transplantation or implantation of long-term mechanical circulatory support (LTMCS) is required. The purpose of our study was to evaluate the bridge-to-bridge (BTB) concept.
INTRODUCTION
Extracorporeal life support (ECLS) devices provide temporary mechanical circulatory assistance, are usually implanted under emergency conditions in critical patients, and can be utilized as a 'bridge-to-recovery', 'bridge-to-transplantation' or 'bridge-tobridge' (BTB), i.e. in patients on ECLS support awaiting long-term mechanical circulatory support (LTMCS) [1] [2] [3] [4] . This phase of temporary assistance, while ensuring satisfactory haemodynamics, facilitates complementary diagnostic explorations that can guide the decision-making algorithm. Nevertheless, some authors have criticized the use of temporary assistance by ECLS with the aim of stabilizing the patient and recommend the implantation of an LTMCS device as the first-line therapeutic strategy [5, 6] .
Of course, BTB is not a goal, but in our institution as well as in many others, we have to face emergent implantation of ECLS in patients with profound cardiogenic shock and because many of them will not recover, they will be candidates for BTB. Thus, the purpose of our study is to analyse the difference shown by BTB versus direct implantation of LTMCS patients at the time of implantation and try to understand if BTB is an efficient concept. We analysed the evolution of the biological profiles in these two groups of patients in order to identify, among the BTB patients, the biological parameters that can be considered negative prognostic factors in terms of outcome during LTMCS, and thus to select those patients most suitable for a BTB strategy.
MATERIALS AND METHODS

Study population
Between 1 January 2004 and 30 April 2010, 817 patients were assisted by ECLS (veno-arterial ECMO) for cardiogenic shock: 420 were implanted using our Mobile Unit of Circulatory Support and, among these, LTMCS was subsequently established in 49 patients (the BTB group). Over the same period ( Fig. 1) , 48 patients were assisted by LTMCS utilized as the first-line therapeutic strategy (the 'bridge' group).
Indications for mechanical circulatory assistance
A mechanical circulatory assistance device was implanted for cardiogenic shock in all cases. The different aetiologies of cardiogenic shock are presented in Table 1 . Every patient under mechanical circulatory assistance met the following criteria: (i) decompensated heart failure under inotropic support (epinephrine > 0.2 µg/kg/min or dobutamine > 20 µg/kg/min ± norepinephrine > 0.2 µg/kg/min) and/or need to increase the inotropic support and/or intra-aortic balloon pump; (ii) signs of cardiogenic shock (peripheral hypoperfusion, polypnoea, sweats, tachycardia, collapse, oligo/ anuria, abdominal pains, nausea, syncope, arrhythmias under inotropic support, ionic disorders, worsening of the hepatic and/or renal functions, wedge pressure >18 mmHg, cardiac index <2 l/min/ m 2 ); catheterism was rarely available under emergency conditions. In emergency cases of cardiogenic shock or haemodynamic instability occurring remotely from our cardiac surgery department, the implanted assistance device was an ECLS. In the absence of recovery and transplantation, patients surviving on ECLS were switched to an LTMCS (the BTB group). In the case of chronic or stable heart failure (INTERMACS 2-3), LTMCS was implanted as the first-line intervention (the 'bridge' group).
Type of mechanical circulatory assistance
Temporary mechanical circulatory assistance with extracorporeal life support. The ECLS system consists of a polyvinylchloride circuit with a membrane oxygenator and a centrifugal pump (Rotaflow, Jostra-Maquet; Sorin Group; BiomedicusCarmeda, Medtronic). Venous and arterial cannulas were surgically placed in an intrathoracic position (central ECLS) or in the femoral vessels ( peripheral ECLS): (arterial cannula: 15-21 French; venous cannula diameter: 20-30 French). In the case of peripheral femoro-femoral ECLS, a catheter of arterial reperfusion (5-7 French) was introduced into the superficial femoral artery in order to reduce the risk of lower limb ischaemia.
ECLS patients were monitored with echocardiography. The target anticoagulation level with continuous unfractionated heparin infusion was an activated clotting time of 150-180 s or a blood heparin level of 0.3-0.5 UI/ml. Acetylsalicylic acid was included in the treatment protocol at an antiplatelet dose if the platelet count exceeded 75-100 × 10 9 /l and there was no major bleeding. In the case of major bleeding, heparin infusion and acetylsalicylic acid therapy were suspended.
Long-term mechanical circulatory support. The various LTMCS devices utilized in our study groups are described in Table 1 .
Evaluation of biological parameters
The biological data were related to the tissue perfusion state ( plasmatic concentrations of lactates, blood pH), hepatic function ( prothrombin time, plasmatic concentrations of transaminases, total bilirubin, direct bilirubin, alkaline phosphatase), renal function (plasmatic concentrations of urea and creatinine), C-reactive protein and leucocyte number. The biological data were those resulting from the biological assessments carried out immediately before implantation of the ECLS ('0' = pre-ECLS), the day after implantation of the ECLS ( J1), immediately before the implantation of an LTMCS ('pi' = preimplantation), and then Day 1 (POD1), 7 and 30 after LTMCS implantation.
Statistical analysis
The data were collected by means of Excel software and were analysed using the SPSS® software version 11.5. There was no loss to the follow-up, because each patient had systematical and regular consultations.
Descriptive analysis. We calculated simple frequencies and relative frequencies (percentages) for categorical variables. We calculated means, medians and standard deviations, and determined the minimum and maximum sample values for the continuous variables.
Analytical analysis Comparisons of means. Pairs of means in independent series
were compared using Student's paired t-test and, in cases of nonvalidity of this test, non-parametric Mann-Whitney test. Pairs of means in paired series were compared using Student's paired t-test and, in cases of variables <30, the non-parametric Wilcoxon test. The comparison of several means in paired series (kinetic study of the biological variables) was conducted using the nonparametric Friedman test.
Comparisons of percentages. Comparisons of percentages in
independent series were carried out using Pearson's χ 2 test and, in the event of non-validity of this test and comparisons of two percentages, Fisher's exact test.
Survival analysis. Survival data were studied by establishing survival curves according to the Kaplan-Meier method. The time origin of survival was the time of LTMCS. The primary end point was all-cause mortality. The prognostic factors of survival were determined using univariate analysis (factor by factor), comparing the survival curves with the log-rank test and the multivariate analysis using the Cox proportional hazards regression model to evaluate the hazard ratio. For each parameter, the value chosen as the 'limit' for the comparative study of survival was the median. Backwards stepwise selection method was used, introducing factors with a significance of P < 0.15 in the univariate analysis.
Concordance study. The concordance between two categorical variables was measured using Cohen's kappa coefficient. In all statistical tests, the threshold of significance was fixed at 0.05.
RESULTS
Characteristics of the population
The baseline characteristics of the study populations are summarized in Table 1 . The overall mean age was 51.2 ± 12.5 years (range 17-76 years) with a prevalence of males (male-to-female ratio was 4.7). BTB patients were significantly younger (48 vs 54 years). Acute coronary syndrome was significantly more prevalent in the BTB group, while chronic HF was less often a concern. A central approach was performed in 16 patients, and in 42 patients first supported with a peripheral approach, 9 were then supported by a central ECLS and 10 had a vent placement (apical cannulation) because of left ventricular distension or lung failure. The mean follow-up was 30.7 ± 19.1 months. Data were collected prospectively from the computerized databases of our Institution.
Survival study
In our overall population of 97 patients assisted by LTMCS, the survival rate at 5 years was 51.55%. There was no significant difference in survival between patients assisted by LTMCS utilized as the first-line therapeutic strategy (the 'bridge' group) and those assisted by LTMCS after a temporary period of ECLS support (the BTB group, P = 0.76; Fig. 2 ).
Kinetic study of the biological parameters
Comparison of the biological parameters of the 'bridge' group before the implantation of the LTMCS with those of the BTB group before the implantation of ECLS revealed that lactates, transaminases, leucocytes and time of prothrombin were more impaired in the BTB group (Table 2) .
Moreover, in the BTB group, comparison of the biological parameters before the installation of ECLS, the day after ECLS implantation and before the implantation of the LTMCS showed that every parameter other than pH, urea, creatinine, bilirubin and leucocytes improved from the first day of ECLS support. Conversely, total bilirubin and alkaline phosphatase increased (Table 2) . After the period of temporary assistance with ECLS, and before the implantation of LTMCS, biological parameters in the BTB group were comparable with those of the 'bridge' group ( pi) (Fig. 3) , with the exception of lactates and urea, which were lower in the BTB group, and leucocytes, which were higher in this group.
Comparison of the biological parameters before LTMCS of patients who were alive with those of patients who were dead at the end of the study period showed that those who died were in a more critical state on the day of implantation. These patients were in a suboptimal tissue perfusion state (elevated plasmatic concentration of lactates) and showed impaired hepatic and renal function (Table 3) . Moreover, before ECLS implantation, the alkaline phosphatase rate was higher among patients who subsequently died ( Table 3) .
The kinetic study of the biological parameters of the live/dead patients showed that patients who died after LTMCS had improved less under ECLS support than the patients who survived (Table 3) . They showed no correction of their time of prothrombin or their total bilirubin, although both parameters improved among surviving patients (Fig. 3) .
In the univariate analysis, the plasmatic concentration of lactates and total bilirubin before LTMCS implantation and alkaline phosphatase before ECLS implantation were predictive factors of mortality after LTMCS (Table 4 ). The plasmatic concentration of lactates was more frequently high among patients with high rates of total bilirubin (P = 0.003) ( Table 4) .
In the multivariate analysis, the plasmatic concentration of lactates and total bilirubin before LTMCS were independent predictive factors of mortality after LTMCS (Table 4) .
DISCUSSION
The descriptive and analytical analyses of our population revealed differences between the BTB and 'bridge' groups. These differences, related to the two opposite concepts of mechanical circulatory assistance in the case of cardiogenic shock, do not invalidate our analysis because the objective of our work was not to show the superiority of one concept compared with the other. Indeed, the 'bridge' group was used only as a comparison group to show that the BTB concept allowed the Before the implantation of ECLS, the patients were in a situation of tissue hypoperfusion and multiorgan failure, as clearly shown by their biological profiles. In this INTERMACS-I-high-risk group, cardiogenic shock is the cause of such general tissue hypoperfusion and multiorgan failure [7] . In this particular clinical setting, comparison of the biological parameters showed that these patients presented a more impaired tissue perfusion state than patients in the 'bridge' group before the implantation of an LTMCS. Their hepatic cellular function was more highly impaired with higher transaminase levels and lower time of prothrombin levels than in the 'bridge' group. The rapid restoration of satisfactory tissue perfusion with ECLS improved the biological profiles of these patients. This improvement had an early onset and helped restore the initially compromised hepatic function. The ability of ECLS to quickly restore tissue perfusion has been reported previously [4] and gives it a prime role in the treatment of cardiogenic shock. The restoration of tissue perfusion by ECLS means that patients are in a better state of organ perfusion at the time of implantation of an LTMCS compared with the time of implantation of the ECLS. The biological profiles of these patients were not only improved (except for bilirubin) but comparable or even better than those of patients in the 'bridge' group. So, ECLS allows the implantation of an LTMCS in critically ill patients, for whom such assistance is not always possible because of their initially severe clinical condition or the occurrence of cardiogenic shock remotely from a cardiac surgery department.
In our series, the overall survival rate at 36 months was 51.5%. That of the BTB group was 51%, which is comparable with other series [1, 2, 4, 5, [8] [9] [10] . There was no significant survival difference between the bridge and BTB groups. The BTB concept thus does not imply a loss of chance for these patients. These results are comparable with those reported by Pagani et al. [8] , who found a similar rate of survival between their BTB series, and various studies reported in the literature related to LTMCS as the first-line therapeutic strategy [2, 11] .
Some authors [5, 6] have reported the opposite and consider that temporary assistance by ECLS is a risk factor for mortality in LTMCS patients, justifying their reluctance to utilize this type of mechanical circulatory assistance in cases of cardiogenic shock. Other authors [8, [12] [13] [14] have reported that assistance by ECLS is accompanied, at the time of implantation of an LTMCS, by a substantial rate of right ventricular failure and, as a consequence, by the more frequent recourse to devices of right-ventricular or biventricular assistance.
In their opinion, such right ventricular failure is directly dependent on the use of ECLS and can be attributed to pulmonary involvement caused by the inflammatory syndrome which it generates [15, 16] or the severity of the initial haemodynamic condition. We found no evidence of this in our series. Pagani et al. [8] reported the utilization of a right ventricular device in 40% of patients assisted by ECLS, whereas in our series this rate was 47% in the BTB group and 52% in the 'bridge' group. The recourse to a right ventricular device was thus no more frequent in the BTB group but was at least as frequent as in the series of Pagani et al. [8] .
Other studies stating that patients with biventricular devices had a higher morbidity and/or mortality rate [17, 18] also demonstrated that these patients had highly impaired biological profiles (mostly total bilirubin and creatinine) without showing that biventricular assistance systems were an independent factor of morbidity or mortality.
There were no significant difference in terms of mortality according to the aetiology of cardiogenic shock, the central or peripheral configuration of ECLS, LVAD, age and invasive mechanical ventilation before the implantation of ECLS. In the same way, there was no significant difference in terms of mortality according to the location at which the ECLS was implanted, totally justifying the role of our Mobile Unit of Circulatory Support. In fact, the implantation of ECLS performed by a trained team allows the rapid and effective restoration of satisfactory haemodynamics in cardiogenic shock patients, even at a distance from a cardiac surgery department. We also observed that patients who died after the implantation of LTMCS improved less under ECLS than patients who survived. In fact, the plasmatic concentration of lactates was invariably high and the time of prothrombin was always low. We also observed an increase in the total bilirubin in patients who subsequently died, but not in those who survived. This observation indicates that patients who do not improve sufficiently under ECLS will not benefit from LTMCS. Severe and prolonged tissue hypoperfusion, which is responsible for irreversible end-organ dysfunction, is, in our opinion, probably the leading cause. Indeed, we observed a statistical correlation between the increase in the plasmatic concentration of lactates and that of total bilirubin before the implantation of LTMCS.
However, although plasmatic concentrations of urea and creatinine were higher among patients who died, we were unable to demonstrate that they were independent prognostic factors. This is probably related to the intrinsic limits of our study rather than to the evaluation of renal function, according to the utilization of haemofiltration systems. In the scientific literature, impairment of renal function is reported to be an important risk factor for morbidity and mortality during LTMCS [19] [20] [21] [22] [23] .
As outlined above, ECLS rapidly and effectively restores tissue perfusion but patients who do not improve or improve only a little under ECLS will not draw any benefit from the implantation of LTMCS. This fact encourages, in our opinion, the requirement for the normalization of biological parameters and in particular of hepatic function before considering the implantation of LTMCS. Some authors [21, 24, 25] have reported selection criteria for the implantation of LTMCS.
This ECLS phase of haemodynamic stabilization and diagnostic exploration allows the selection, from among patients who cannot be weaned from ECLS or transplanted, of those who can be directed towards LTMCS and those for whom the prolongation of medical care does not appear reasonable. The BTB concept, which makes it possible to restore satisfactory tissue perfusion quickly and effectively at an acceptable cost, thus fits well into the management of healthcare outlay.
In conclusion, ECLS facilitates the use of LTMCS in critical patients, for whom such assistance is not always initially possible because of their clinical condition or because of the occurrence of cardiogenic shock remotely from a cardiac surgery department. The survival of these patients is comparable with that of patients assisted with LTMCS as the first-line therapeutic strategy. 
